Drug Pricing Transparency and Accountability Act

This bill creates a 2-year moratorium on new hospital registrations for the 340B drug discount program, which provides discounted prescription drugs to certain hospitals serving low-income patients. It establishes strict eligibility criteria for hospitals to participate in the program, including requirements for outpatient services, Medicare cost report documentation, and adherence to charity care policies. The bill mandates detailed annual reporting of financial information about 340B drug purchases, including revenue, acquisition costs, patient payment sources, and charity care costs, with this data made publicly available. It also requires the use of a specific "340B modifier" (JG) on claims for reimbursement of 340B drugs across Medicare, Medicaid, and other programs. These provisions aim to increase transparency and accountability in how hospitals use the 340B program.